Dr. Dirk Arnold on Sirflox and its Effect on Liver Metastases
Dirk Arnold, MD, PhD, Professor and Head Dept. Hematology and Medical Oncology at Tumor Biology Center in Freiburg, Germany, talks about sirflox and its phase III trials on whether or not it can properly add local ablative treatment to diffuse metastasization of the liver.
Dirk Arnold, MD, PhD, Professor and Head Dept. Hematology and Medical Oncology at Tumor Biology Center in Freiburg, Germany, talks about Sirflox, its phase III trials, and whether or not it can properly add local ablative treatment to diffuse metastasization of the liver.
Arnold calls the results of the study surprising. He says that while the progression-free survival in the liver turned out to be impressive, the overall progression-free survival of patients that participated in the study were not nearly as good.
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
